A1 Refereed original research article in a scientific journal
SGLT2 inhibition reduces myocardial oxygen consumption
Authors: Søndergaard Esben, Lauritzen Esben S, Lauritsen Katrine M, Åkerblom Axel, Nuutila Pirjo, Oldgren Jonas, Gormsen Lars C
Publisher: Elsevier
Publication year: 2022
Journal: Metabolism open
Journal name in source: Metabolism open
Journal acronym: Metabol Open
Article number: 100207
Volume: 15
ISSN: 2589-9368
eISSN: 2589-9368
DOI: https://doi.org/10.1016/j.metop.2022.100207
Web address : https://www.sciencedirect.com/science/article/pii/S2589936822000457?via%3Dihub
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/177975645
Aims/hypothesis: SGLT2 inhibition is associated with a reduced risk of cardiac disease that is still largely unexplained. According to one hypothesis, improved myocardial energetics may explain the cardioprotective effects of SGLT2i. However, recent mechanistic studies that have addressed this question have lacked the power to detect discrete but still clinically significant effects.
Methods:We pooled data from two recent randomized clinical trials and performed a meta-analysis to determine the effect of SGLT2 inhibition on myocardial oxygen consumption and myocardial external efficiency measured by positron emission tomography.
Results:SGLT2 inhibition reduced myocardial oxygen consumption (−1.06 [95%CI: 0.22–1.89] mL/100 g/min (n = 59, p = 0.01)), but did not affect myocardial external efficiency (2.22 [95%CI: 0.66-5.11] % (n = 59, p = 0.13))
Conclusions: /interpretation SGLT2 inhibition reduces myocardial oxygen consumption at rest, which may contribute to the drugs’ cardioprotective effects.
Downloadable publication This is an electronic reprint of the original article. |  |
